NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RPTX

Repare Therapeutics Inc

Jul 03 • 09:59AM ET

1.46

Dollar change +0.02
Percentage change 1.39	%

Healthcare • Biotechnology • Canada • NASD

Peers: AMGN GILD REGN BIIB VRTX ALNY BMRN INCY NBIX SRPT

| Held by: VHT GWX CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.01	Insider Own	28.25%	Shs Outstand	42.89M	Perf Week	3.55%
Market Cap	62.62M	Forward P/E	-	EPS next Y	-1.55	Insider Trans	-0.31%	Shs Float	30.77M	Perf Month	0.69%
Enterprise Value	-60.24M	PEG	-	EPS next Q	-0.56	Inst Own	42.30%	Short Float	1.93%	Perf Quarter	36.45%
Income	-127.89M	P/S	58.52	EPS this Y	-5.50%	Inst Trans	-10.66%	Short Ratio	2.31	Perf Half Y	16.80%
Sales	1.07M	P/B	0.50	EPS next Y	26.54%	ROA	-62.83%	Short Interest	0.59M	Perf YTD	11.45%
Book/sh	2.92	P/C	0.50	EPS next 5Y	-5.52%	ROE	-71.64%	52W High	4.29 -65.97%	Perf Year	-56.16%
Cash/sh	2.90	P/FCF	-	EPS past 3/5Y	10.94% -21.89%	ROIC	-102.24%	52W Low	0.89 64.04%	Perf 3Y	-89.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	91.62% -	Gross Margin	-142.87%	Volatility	3.95% 3.61%	Perf 5Y	-95.48%
Dividend TTM	-	EV/Sales	-56.30	EPS Y/Y TTM	-177.17%	Oper. Margin	-12125.72%	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.42	Sales Y/Y TTM	-98.90%	Profit Margin	-11919.29%	RSI (14)	59.22	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.42	EPS Q/Q	-335.92%	SMA20	1.86%	Beta	0.91	Target Price	5.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-100.00%	SMA50	5.09%	Rel Volume	0.18	Prev Close	1.44
Employees	129	LT Debt/Eq	0.00	Earnings	May 13 AMC	SMA200	-24.27%	Avg Volume	256.96K	Price	1.46
IPO	Jun 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.40% 199.99%	Trades		Volume	5,721	Change	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-23	Upgrade	Stifel	Hold → Buy	$11 → $16
Feb-03-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $15
Jan-06-23	Initiated	CapitalOne	Overweight	$28
Apr-12-22	Downgrade	Stifel	Buy → Hold	$11
Mar-17-22	Resumed	Goldman	Buy	$43
Sep-23-21	Initiated	Stifel	Buy	$48
Sep-13-21	Initiated	H.C. Wainwright	Buy	$54
Jun-28-21	Initiated	Guggenheim	Buy	$46
Mar-01-21	Initiated	Berenberg	Buy	$51
Oct-28-20	Initiated	Northland Capital	Outperform	$38
Jul-14-20	Initiated	Piper Sandler	Overweight
Jul-14-20	Initiated	Morgan Stanley	Overweight	$37
Jul-14-20	Initiated	Goldman	Neutral	$27
Jul-14-20	Initiated	Cowen	Outperform

Show Previous Ratings

May-13-25 04:05PM	Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results (Business Wire) +5.15% -8.74%
May-12-25 09:15AM	CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 04:27AM	Repare signs out-licensing deal with DCx Biotherapeutics (Pharmaceutical Technology)
May-01-25 07:00AM	Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics (Business Wire)
07:00AM	Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates (Business Wire)
01:00PM	Loading…
Apr-25-25 01:00PM	Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 (Business Wire) -6.02%
Mar-31-25 04:39PM	Repare Therapeutics Announces Leadership Transitions (Business Wire) -6.10%
Mar-11-25 12:00PM	What Makes Repare Therapeutics (RPTX) a New Buy Stock (Zacks)
Mar-07-25 04:05PM	Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-03-25 07:05AM	Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Jan-24-25 09:55AM	Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jan-21-25 09:35AM	Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-09-25 04:05PM	Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions (Business Wire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire)
Dec-13-24 12:09PM	Why Is Repare Therapeutics Stock Trading Lower On Friday? (Benzinga) -55.42%
11:45AM	Loading…
11:45AM	Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results (GuruFocus.com)
10:28AM	Repare Therapeutics eyes Phase III cancer study after Mythic trial success (Clinical Trials Arena)
Dec-12-24 04:20PM	Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial (Business Wire) +10.28%
Dec-10-24 04:05PM	Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial (Business Wire) +19.60%
Nov-12-24 07:05AM	Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib (Business Wire) -5.54%
Nov-07-24 07:05AM	Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-24-24 05:57AM	Repare Therapeutics individualised anaemia management trial shows promise (Clinical Trials Arena)
Oct-23-24 06:05AM	Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial (Business Wire)
Oct-14-24 10:39AM	Repare Therapeutics doses first subject in Phase I solid tumour trial (Clinical Trials Arena) +7.96%
07:05AM	Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol ATPase Inhibitor (Business Wire)
Sep-30-24 04:05PM	Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting (Business Wire)
Sep-23-24 07:05AM	Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers (Business Wire)
Sep-13-24 07:00AM	Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 (Business Wire) +17.67%
Aug-29-24 09:33AM	Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets (Clinical Trials Arena)
05:19AM	Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canadas Evolving Economic Landscape (Insider Monkey)
04:05PM	Loading…
Aug-28-24 04:05PM	Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio (Business Wire)
Aug-27-24 07:05AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire)
Aug-06-24 05:50PM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.05%
04:05PM	Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-16-24 09:00AM	Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund (PR Newswire) +6.94%
Jun-26-24 10:30AM	Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI (Business Wire)
Jun-10-24 07:05AM	Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial (Business Wire)
Jun-06-24 09:59AM	Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag (Zacks)
Jun-05-24 06:28AM	Repare Therapeutics secures FDA Fast Track designation for ovarian cancer therapy (Pharmaceutical Business Review) +13.88%
Jun-04-24 04:05PM	Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer (Business Wire)
Jun-03-24 04:05PM	Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 07:05AM	Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 (Business Wire)
May-08-24 07:39AM	Top Premarket Gainers (MT Newswires) +15.55%
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-07-24 10:55PM	RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 07:05AM	Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition (Business Wire)
07:05AM	Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition (Business Wire)
Apr-26-24 04:05PM	Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors (Business Wire)
Feb-29-24 07:05AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) +5.30%
Feb-28-24 07:36AM	Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023 (GuruFocus.com)
07:05AM	Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 10:00AM	Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) -5.28%
Feb-15-24 07:05AM	Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 (Business Wire)
Feb-13-24 04:45AM	Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock? (Zacks) -15.58%
Feb-12-24 04:05PM	Repare Therapeutics to Regain Global Rights to Camonsertib (Business Wire) +8.80%
Jan-25-24 07:00AM	Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment (Business Wire) +6.95%
Jan-08-24 07:00AM	Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones (Business Wire) +8.32%
Jan-04-24 04:05PM	Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer (Business Wire) -5.21%
Dec-29-23 04:05PM	Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans (Business Wire)
Nov-20-23 08:19AM	Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why (Zacks)
Nov-15-23 07:00AM	Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol Inhibitor (Business Wire) +29.66%
Nov-09-23 11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga) -10.83%
08:16AM	Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline Progress (GuruFocus.com)
07:00AM	Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-07-23 07:00AM	Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast (Business Wire)
Nov-06-23 11:35AM	Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Ken Griffin, Guardian Capital LP, Two Sigma, Repare Therapeutics Inc. (RPTX), Remitly Global Inc (RELY), and More (Insider Monkey) +14.70%
07:00AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire)
Oct-13-23 09:40AM	Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib (Business Wire) -5.71%
Oct-11-23 09:35AM	Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround (Zacks) -7.40%
Oct-09-23 09:35AM	Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks (Zacks)
Oct-03-23 07:00AM	Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire)
Sep-20-23 04:26AM	Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength? (Zacks)
Sep-19-23 07:00AM	Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire) +12.23%
Sep-06-23 07:00AM	Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
Aug-16-23 02:54PM	Wall Street Thinks This Cathie Wood Stock Could Jump by 187% (Motley Fool)
Aug-09-23 05:40PM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +17.10%
04:05PM	Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-05-23 03:30PM	10 Oversold Canadian Stocks To Buy (Insider Monkey)
Jul-16-23 10:36AM	Repare Therapeutics (NASDAQ:RPTX) shareholders have endured a 52% loss from investing in the stock three years ago (Simply Wall St.)
Jun-08-23 09:49AM	Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials (Benzinga)
07:00AM	Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-07-23 04:05PM	Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials (Business Wire)
Jun-06-23 07:00AM	Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors (Business Wire)
Jun-05-23 06:36AM	Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap touched US$481m last week, benefiting both private equity firms who own 34% as well as institutions (Simply Wall St.)
Jun-02-23 07:00AM	Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights (Business Wire) +7.43%
May-22-23 07:00AM	Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-14-23 08:04AM	Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31% (Simply Wall St.)
May-12-23 06:19AM	Earnings Update: Repare Therapeutics Inc. (NASDAQ:RPTX) Just Reported And Analysts Are Boosting Their Estimates (Simply Wall St.)
May-11-23 06:13AM	A Look At The Intrinsic Value Of Repare Therapeutics Inc. (NASDAQ:RPTX) (Simply Wall St.)
May-09-23 06:55PM	Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results (Business Wire)
May-03-23 09:55AM	How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72% (Zacks)
Apr-28-23 04:05PM	Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors (Business Wire)
Apr-18-23 02:32PM	Repare Therapeutics Inc.'s (NASDAQ:RPTX) Share Price Is Matching Sentiment Around Its Revenues (Simply Wall St.)
10:15AM	Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting (Business Wire)
Mar-29-23 07:25AM	We're Interested To See How Repare Therapeutics (NASDAQ:RPTX) Uses Its Cash Hoard To Grow (Simply Wall St.)
Mar-14-23 04:58PM	Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306 (Business Wire)
Mar-02-23 05:39AM	Repare Therapeutics Full Year 2022 Earnings: US$0.69 loss per share (vs US$2.83 loss in FY 2021) (Simply Wall St.)

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Koehler Maria	EVP, CHIEF MEDICAL OFFICER	Mar 12 '25	Sale	1.14	3,596	4,099	227,813	Mar 14 04:30 PM
Zinda Michael	EVP, CHIEF SCIENTIFIC OFFICER	Mar 12 '25	Sale	1.14	5,611	6,397	80,297	Mar 14 04:30 PM
Forte Steve	EVP, CHIEF FINANCIAL OFFICER	Mar 12 '25	Sale	1.14	6,884	7,848	54,786	Mar 14 04:30 PM
Segal Lloyd Mitchell	PRESIDENT AND CEO	Mar 12 '25	Sale	1.14	21,179	24,144	124,394	Mar 14 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RPTX

Repare Therapeutics Inc

Upgrade your FINVIZ experience